SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: IMMUNE NETWORK RESEARCH (VSE:IMM)

No earlier versions found for this Subject.


Return to IMMUNE NETWORK RESEARCH (VSE:IMM)
 
This company if focused on HIV related research. The stock price is low, indicative of a start-up company.Their scientists are collaborating with very reputable institutions and their objective is an effective Aids vaccine. This is possibly a worthwhile longshot @< 30 cents CDN.
Website is <http//:www.stockgroup.com/imm.html>.
(VSE:INI)

Dan Byrne

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News